Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesTrends in RA patients' adherence to subcutaneous anti-TNF therapies and costs
Current Medical Research and Opinion, 06/26/09
Borah BJ et al. – Study reports that etanercept (ETA) users had longer treatment duration, were more likely to adhere to their medication regimen and had lower rheumatoid arthritis (RA)-related pharmacy and RA-related total costs compared with adalimumab (ADA) users.
Methods- Main objectives of study were:
- To examine adherence to ADA and ETA and health care costs in RA pts, and
- To explore the association between adherence, utilization and costs
- RA pts treated with etanercept or adalimumab during Jan 2005-Dec 2005 were identified
- Patient adherence and costs were assessed during the 1 yr post-index period (first dispensing date)
- Nonadherence was modeled using logistic regression
- Hazard ratios (HR) comparing time to discontinuation were estimated using Cox proportional hazard (PH) models
- Compared with ADA users, ETA users had longer average treatment duration
- Unadjusted adherence rates for naïve and existing users were 63% and 70% (ADA), and 65% and 73% (ETA)
- Compared with ETA users, ADA users were more likely to be nonadherent
- Existing ADA users were more likely to discontinue their medication than existing ETA users
- Compared with ADA users, ETA users had lower RA-related pharmacy costs and RA-related total costs
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Osteoarthritis: A review of treatment options
Geriatrics, 10/21/09
Doxycycline for osteoarthritis of the knee or hip
Cochrane Reviews, 10/23/09
Bisphosphonate therapy: When not to monitor BMD
The Journal of Family Practice, 11/02/09
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Sponsor
Article Search
Sponsor